200 related articles for article (PubMed ID: 25384689)
41. Empirical treatment of candidemia in intensive care units: fluconazole or broad-spectrum antifungal agents?
Guinea J; Peláez T; Rodríguez-Créixems M; Torres-Narbona M; Muñoz P; Alcalá L; Bouza E
Med Mycol; 2009; 47(5):515-20. PubMed ID: 18972315
[TBL] [Abstract][Full Text] [Related]
42. Effect of fluconazole consumption on long-term trends in candidal ecology.
Blot S; Janssens R; Claeys G; Hoste E; Buyle F; De Waele JJ; Peleman R; Vogelaers D; Vandewoude K
J Antimicrob Chemother; 2006 Aug; 58(2):474-7. PubMed ID: 16757503
[TBL] [Abstract][Full Text] [Related]
43. Vulvovaginal candidiasis: species distribution, fluconazole resistance and drug efflux pump gene overexpression.
Zhang JY; Liu JH; Liu FD; Xia YH; Wang J; Liu X; Zhang ZQ; Zhu N; Yan-Yan ; Ying Y; Huang XT
Mycoses; 2014 Oct; 57(10):584-91. PubMed ID: 24962255
[TBL] [Abstract][Full Text] [Related]
44. Invasive fungal infections following liver transplantation: incidence, risk factors, survival, and impact of fluconazole-resistant Candida parapsilosis (2003-2007).
Raghuram A; Restrepo A; Safadjou S; Cooley J; Orloff M; Hardy D; Butler S; Koval CE
Liver Transpl; 2012 Sep; 18(9):1100-9. PubMed ID: 22577087
[TBL] [Abstract][Full Text] [Related]
45. Species distribution and fluconazole susceptibility of Candida clinical isolates in a medical center in 2002.
Wang JL; Chang SC; Hsueh PR; Chen YC
J Microbiol Immunol Infect; 2004 Aug; 37(4):236-41. PubMed ID: 15340652
[TBL] [Abstract][Full Text] [Related]
46. Eight-year surveillance of non-albicans Candida spp. in an oncology department prior to and after fluconazole had been introduced into antifungal prophylaxis.
Kunova A; Trupl J; Demitrovicova A; Jesenska Z; Grausova S; Grey E; Pichna P; Kralovicova K; Sorkovska D; Krupova I; Spanik S; Studena M; Koren P; Krcmery V
Microb Drug Resist; 1997; 3(3):283-7. PubMed ID: 9271000
[TBL] [Abstract][Full Text] [Related]
47. Emergence of non-albicans Candida species and antifungal resistance in a tertiary care hospital.
Capoor MR; Nair D; Deb M; Verma PK; Srivastava L; Aggarwal P
Jpn J Infect Dis; 2005 Dec; 58(6):344-8. PubMed ID: 16377864
[TBL] [Abstract][Full Text] [Related]
48. Candida spp. in vitro susceptibility profile to four antifungal agents. Resistance surveillance study in Venezuelan strains.
Panizo MM; Reviákina V; Dolande M; Selgrad S
Med Mycol; 2009 Mar; 47(2):137-43. PubMed ID: 18651308
[TBL] [Abstract][Full Text] [Related]
49. Invasive Candidiasis in Brescia, Italy: Analysis of Species Distribution and Antifungal Susceptibilities During Seven Years.
De Francesco MA; Piccinelli G; Gelmi M; Gargiulo F; Ravizzola G; Pinsi G; Peroni L; Bonfanti C; Caruso A
Mycopathologia; 2017 Oct; 182(9-10):897-905. PubMed ID: 28597394
[TBL] [Abstract][Full Text] [Related]
50. Epidemiology of invasive candidiasis in a surgical intensive care unit: an observational study.
Aguilar G; Delgado C; Corrales I; Izquierdo A; Gracia E; Moreno T; Romero E; Ferrando C; Carbonell JA; Borrás R; Navarro D; Belda FJ
BMC Res Notes; 2015 Sep; 8():491. PubMed ID: 26415526
[TBL] [Abstract][Full Text] [Related]
51. Differential association of fluconazole dose and dose/MIC ratio with mortality in patients with Candida albicans and non-albicans bloodstream infection.
Brosh-Nissimov T; Ben-Ami R
Clin Microbiol Infect; 2015 Nov; 21(11):1011-7. PubMed ID: 26183300
[TBL] [Abstract][Full Text] [Related]
52. Candidemia: the impact of antifungal prophylaxis in a surgical intensive care unit.
Swoboda SM; Merz WG; Lipsetta PA
Surg Infect (Larchmt); 2003; 4(4):345-54. PubMed ID: 15012861
[TBL] [Abstract][Full Text] [Related]
53. Stable susceptibility of Candida blood isolates to fluconazole despite increasing use during the past 10 years.
Chen YC; Chang SC; Luh KT; Hsieh WC
J Antimicrob Chemother; 2003 Jul; 52(1):71-7. PubMed ID: 12775680
[TBL] [Abstract][Full Text] [Related]
54. National surveillance of antifungal susceptibility of Candida species in South Korean hospitals.
Yoo JI; Choi CW; Lee KM; Kim YK; Kim TU; Kim EC; Joo SI; Yun SH; Lee YS; Kim BS
Med Mycol; 2009; 47(5):554-8. PubMed ID: 18819023
[TBL] [Abstract][Full Text] [Related]
55. Distribution and antifungal susceptibility of Candida species causing nosocomial candiduria.
Ozhak-Baysan B; Ogunc D; Colak D; Ongut G; Donmez L; Vural T; Gunseren F
Med Mycol; 2012 Jul; 50(5):529-32. PubMed ID: 21988703
[TBL] [Abstract][Full Text] [Related]
56. Fluconazole Doses Used for Prophylaxis of Invasive Fungal Infection in Neonatal Intensive Care Units: A Network Meta-Analysis.
Leonart LP; Tonin FS; Ferreira VL; Tavares da Silva Penteado S; de Araújo Motta F; Pontarolo R
J Pediatr; 2017 Jun; 185():129-135.e6. PubMed ID: 28285752
[TBL] [Abstract][Full Text] [Related]
57. Candidemia in patients with hematologic malignancies in the era of new antifungal agents (2001-2007): stable incidence but changing epidemiology of a still frequently lethal infection.
Sipsas NV; Lewis RE; Tarrand J; Hachem R; Rolston KV; Raad II; Kontoyiannis DP
Cancer; 2009 Oct; 115(20):4745-52. PubMed ID: 19634156
[TBL] [Abstract][Full Text] [Related]
58. Epidemiology of candidemia in Swiss tertiary care hospitals: secular trends, 1991-2000.
Marchetti O; Bille J; Fluckiger U; Eggimann P; Ruef C; Garbino J; Calandra T; Glauser MP; Täuber MG; Pittet D;
Clin Infect Dis; 2004 Feb; 38(3):311-20. PubMed ID: 14727199
[TBL] [Abstract][Full Text] [Related]
59. Antifungal susceptibilities of Candida species isolated from urine culture.
Toka Özer T; Durmaz S; Yula E
J Infect Chemother; 2016 Sep; 22(9):629-32. PubMed ID: 27452427
[TBL] [Abstract][Full Text] [Related]
60. Activities of fluconazole and voriconazole against bloodstream isolates of Candida glabrata and Candida krusei: a 14-year study in a Spanish tertiary medical centre.
Quindós G; Sánchez-Vargas LO; Villar-Vidal M; Eraso E; Alkorta M; Hernández-Almaraz JL
Int J Antimicrob Agents; 2008 Mar; 31(3):266-71. PubMed ID: 18054468
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
